drugset / Trial / NCT02857920
Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors
Phase 1/2
Completed
45 enrolled
Fuda Cancer Hospital, Guangzhou
Shenzhen Hank Bioengineering Institute · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of this study is the safety and efficacy of Bevacizumab plus allogeneic natural killer (NK) immunotherapy to many kinds of recurrent solid tumors.
Timeline
- Start
- 2016-08-01
- Primary completion
- 2017-08-01
- Completion
- 2019-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | Intravenous |
| Subject | NK immunotherapy | Cell therapy | 8 cells | Intravenous |
| Subject | NK immunotherapy | Cell therapy | 10 cells | Intravenous |